Brian Schwartz MD

Infinity Pharmaceuticals, Inc.

Appearances

Short Talk: Eganelisib (IPI-549) Activity as a Macrophage Reprogramming Therapeutic Candidate in 1L Metastatic TNBC, 2L Metastatic Urothelial Cancer and Other Solid Tumors
Date
June 21, 2021
Speaker
Brian Schwartz, MD
Infinity Pharmaceuticals, Inc.
Free
Standard Price

Privacy Policy Update: We value your privacy and want you to understand how your information is being used. To make sure you have current and accurate information about this sites privacy practices please visit the privacy center by clicking here.

Brian Schwartz MD

Infinity Pharmaceuticals, Inc.

Appearances

Short Talk: Eganelisib (IPI-549) Activity as a Macrophage Reprogramming Therapeutic Candidate in 1L Metastatic TNBC, 2L Metastatic Urothelial Cancer and Other Solid Tumors

Speaker